FR2823222B1 - Vaccin contre le virus de la fievre du nil - Google Patents

Vaccin contre le virus de la fievre du nil

Info

Publication number
FR2823222B1
FR2823222B1 FR0104737A FR0104737A FR2823222B1 FR 2823222 B1 FR2823222 B1 FR 2823222B1 FR 0104737 A FR0104737 A FR 0104737A FR 0104737 A FR0104737 A FR 0104737A FR 2823222 B1 FR2823222 B1 FR 2823222B1
Authority
FR
France
Prior art keywords
fever virus
vaccine against
nile fever
nile
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0104737A
Other languages
English (en)
French (fr)
Other versions
FR2823222A1 (fr
Inventor
Sheena May Loosmore
Jean Christophe Franc Audonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial SAS
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0104737A priority Critical patent/FR2823222B1/fr
Application filed by Merial SAS, Merial Inc filed Critical Merial SAS
Priority to DK02759818.4T priority patent/DK1377660T3/en
Priority to MXPA03008998A priority patent/MXPA03008998A/es
Priority to ES02759818.4T priority patent/ES2566044T3/es
Priority to HK04104755.3A priority patent/HK1061868B/xx
Priority to JP2002579985A priority patent/JP4426761B2/ja
Priority to RU2003132455/13A priority patent/RU2283138C2/ru
Priority to PL365210A priority patent/PL207584B1/pl
Priority to CA2448796A priority patent/CA2448796C/en
Priority to EP02759818.4A priority patent/EP1377660B1/fr
Priority to SI200231069A priority patent/SI1377660T1/sl
Priority to ES15162832T priority patent/ES2767413T3/es
Priority to PCT/FR2002/001200 priority patent/WO2002081621A2/fr
Priority to EP15162832.8A priority patent/EP2979705B1/fr
Priority to PL391444A priority patent/PL210306B1/pl
Priority to HU0401868A priority patent/HU230122B1/hu
Priority to IL15820402A priority patent/IL158204A0/xx
Priority to AU2002307971A priority patent/AU2002307971B2/en
Priority to BRPI0208896A priority patent/BRPI0208896B1/pt
Publication of FR2823222A1 publication Critical patent/FR2823222A1/fr
Priority to ZA2003/07620A priority patent/ZA200307620B/en
Priority to IL158204A priority patent/IL158204A/en
Priority to US10/679,520 priority patent/US20050031641A1/en
Priority to US10/714,781 priority patent/US7740863B2/en
Application granted granted Critical
Publication of FR2823222B1 publication Critical patent/FR2823222B1/fr
Priority to HK16106775.0A priority patent/HK1219412B/xx
Priority to IL185263A priority patent/IL185263A0/en
Priority to US12/758,500 priority patent/US8535682B2/en
Priority to HUS1500047C priority patent/HUS1500047I1/hu
Priority to CY20161100275T priority patent/CY1117676T1/el
Priority to FR16C0014C priority patent/FR16C0014I2/fr
Priority to NL300806C priority patent/NL300806I2/nl
Priority to LTPA2016011C priority patent/LTC1377660I2/lt
Priority to BE2016C021C priority patent/BE2016C021I2/fr
Priority to LU93048C priority patent/LU93048I2/xx
Priority to CY2016018C priority patent/CY2016018I1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0104737A 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil Expired - Lifetime FR2823222B1 (fr)

Priority Applications (34)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
SI200231069A SI1377660T1 (sl) 2001-04-06 2002-04-05 Cepivo proti virusu Zahodnega Nila
ES02759818.4T ES2566044T3 (es) 2001-04-06 2002-04-05 Vacuna contra el virus de la fiebre del Nilo
HK04104755.3A HK1061868B (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
JP2002579985A JP4426761B2 (ja) 2001-04-06 2002-04-05 ウエストナイル熱ウイルスに対するワクチン
RU2003132455/13A RU2283138C2 (ru) 2001-04-06 2002-04-05 Вакцина против вируса западно-нильской лихорадки
PL365210A PL207584B1 (pl) 2001-04-06 2002-04-05 Szczepionka do ochrony koni, psów, kotów, bydła, świń oraz ptaków przed wirusem zachodniego Nilu (WN)
CA2448796A CA2448796C (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
EP02759818.4A EP1377660B1 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil
PL391444A PL210306B1 (pl) 2001-04-06 2002-04-05 Kompozycja szczepionkowa do indukcji zabezpieczającej odpowiedzi immunologicznej przed wirusem zachodniego Nilu (WNV)
ES15162832T ES2767413T3 (es) 2001-04-06 2002-04-05 Vacuna contra el virus de la fiebre del Nilo
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil
EP15162832.8A EP2979705B1 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fièvre du nil
MXPA03008998A MXPA03008998A (es) 2001-04-06 2002-04-05 Vacuna contra el virus de la fiebre del nilo.
HU0401868A HU230122B1 (hu) 2001-04-06 2002-04-05 Rekombináns vakcina West Nile vírus ellen
IL15820402A IL158204A0 (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
AU2002307971A AU2002307971B2 (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
BRPI0208896A BRPI0208896B1 (pt) 2001-04-06 2002-04-05 vacina contra o vírus da febre do nilo
DK02759818.4T DK1377660T3 (en) 2001-04-06 2002-04-05 Vaccine against nilfeb ervirus
ZA2003/07620A ZA200307620B (en) 2001-04-06 2003-09-30 Vaccine against the nile fever virus
IL158204A IL158204A (en) 2001-04-06 2003-10-01 Vaccine composition for inducing a protective immune response against the west nile virus
US10/679,520 US20050031641A1 (en) 2001-04-06 2003-10-06 Recombinant vaccine against West Nile Virus
US10/714,781 US7740863B2 (en) 2001-04-06 2003-11-17 Recombinant vaccine against West Nile Virus
HK16106775.0A HK1219412B (en) 2001-04-06 2004-07-02 Vaccine against west nile fever
IL185263A IL185263A0 (en) 2001-04-06 2007-08-14 Vaccine against the nile fever virus
US12/758,500 US8535682B2 (en) 2001-04-06 2010-04-12 Recombinant vaccine against West Nile Virus
HUS1500047C HUS1500047I1 (hu) 2001-04-06 2015-09-18 Rekombináns vakcina West Nile vírus ellen
CY20161100275T CY1117676T1 (el) 2001-04-06 2016-04-06 Εμβολιο κατα του ιου του δυτικου νειλου
FR16C0014C FR16C0014I2 (fr) 2001-04-06 2016-04-19 Vaccin contre le virus de la fievre du nil
LTPA2016011C LTC1377660I2 (lt) 2001-04-06 2016-04-20 Vakcina nuo Nilo karštligės viruso
NL300806C NL300806I2 (OSRAM) 2001-04-06 2016-04-20
BE2016C021C BE2016C021I2 (OSRAM) 2001-04-06 2016-04-26
LU93048C LU93048I2 (fr) 2001-04-06 2016-04-26 Proteq west nile
CY2016018C CY2016018I1 (el) 2001-04-06 2016-05-20 Εμβολιο κατα του ιου του δυτικου νειλου

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil

Publications (2)

Publication Number Publication Date
FR2823222A1 FR2823222A1 (fr) 2002-10-11
FR2823222B1 true FR2823222B1 (fr) 2004-02-06

Family

ID=8862055

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0104737A Expired - Lifetime FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
FR16C0014C Active FR16C0014I2 (fr) 2001-04-06 2016-04-19 Vaccin contre le virus de la fievre du nil

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR16C0014C Active FR16C0014I2 (fr) 2001-04-06 2016-04-19 Vaccin contre le virus de la fievre du nil

Country Status (21)

Country Link
EP (2) EP1377660B1 (OSRAM)
JP (1) JP4426761B2 (OSRAM)
AU (1) AU2002307971B2 (OSRAM)
BE (1) BE2016C021I2 (OSRAM)
BR (1) BRPI0208896B1 (OSRAM)
CA (1) CA2448796C (OSRAM)
CY (2) CY1117676T1 (OSRAM)
DK (1) DK1377660T3 (OSRAM)
ES (2) ES2566044T3 (OSRAM)
FR (2) FR2823222B1 (OSRAM)
HU (2) HU230122B1 (OSRAM)
IL (3) IL158204A0 (OSRAM)
LT (1) LTC1377660I2 (OSRAM)
LU (1) LU93048I2 (OSRAM)
MX (1) MXPA03008998A (OSRAM)
NL (1) NL300806I2 (OSRAM)
PL (2) PL207584B1 (OSRAM)
RU (1) RU2283138C2 (OSRAM)
SI (1) SI1377660T1 (OSRAM)
WO (1) WO2002081621A2 (OSRAM)
ZA (1) ZA200307620B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464228C (en) 2000-10-27 2017-01-17 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
AU2002365244B2 (en) 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
CA2510229A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
EP1626708B1 (en) 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
AU2010229675B2 (en) 2009-03-27 2016-02-25 Academia Sinica Methods and compositions for immunization against virus
JP5797190B2 (ja) * 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
CA2282790C (en) * 1997-02-28 2011-04-19 St. Louis University Chimeric flavivirus vaccines
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
PL210451B1 (pl) 1999-06-10 2012-01-31 Merial Sas Szczepionka DNA przeciwko wirusowi nosówki psów (CDV)
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
HUP0401868A2 (hu) 2004-12-28
EP1377660A2 (fr) 2004-01-07
JP2004531521A (ja) 2004-10-14
ZA200307620B (en) 2005-07-27
ES2767413T3 (es) 2020-06-17
PL365210A1 (en) 2004-12-27
FR16C0014I1 (OSRAM) 2016-05-27
SI1377660T1 (sl) 2016-05-31
CA2448796C (en) 2012-11-20
HUS1500047I1 (hu) 2017-03-28
HK1219412A1 (zh) 2017-04-07
LU93048I2 (fr) 2016-06-27
PL210306B1 (pl) 2011-12-30
HUP0401868A3 (en) 2011-06-28
PL207584B1 (pl) 2011-01-31
BR0208896A (pt) 2004-07-20
EP2979705B1 (fr) 2019-10-23
RU2003132455A (ru) 2005-04-27
IL185263A0 (en) 2008-01-06
EP1377660B1 (fr) 2016-01-13
CY2016018I2 (el) 2016-12-14
EP2979705A1 (fr) 2016-02-03
CY1117676T1 (el) 2016-12-14
IL158204A (en) 2013-03-24
BRPI0208896B1 (pt) 2016-06-07
JP4426761B2 (ja) 2010-03-03
IL158204A0 (en) 2004-05-12
HK1061868A1 (zh) 2004-10-08
LTC1377660I2 (lt) 2017-04-25
WO2002081621A2 (fr) 2002-10-17
MXPA03008998A (es) 2004-10-15
BE2016C021I2 (OSRAM) 2021-03-23
FR16C0014I2 (fr) 2016-09-09
HU230122B1 (hu) 2015-08-28
RU2283138C2 (ru) 2006-09-10
DK1377660T3 (en) 2016-03-29
CA2448796A1 (en) 2002-10-17
ES2566044T3 (es) 2016-04-08
FR2823222A1 (fr) 2002-10-11
WO2002081621A3 (fr) 2003-02-20
AU2002307971B2 (en) 2008-01-17
NL300806I2 (OSRAM) 2016-06-09
CY2016018I1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
FR16C0014I2 (fr) Vaccin contre le virus de la fievre du nil
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
DK1407008T3 (da) Influenzavaccinesammens tning
FR14C0016I2 (fr) Vacccin west nile
EP1423141A4 (en) VACCINE
ATE553775T1 (de) Impstoffzusammesetzung
NO20024172D0 (no) Vaksine
EP1572124A4 (en) HCV E1E2 VACCINE COMPOSITIONS
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
DZ3219A1 (fr) Vaccin
NO20033882L (no) Vaksine
DK1523329T3 (da) Viruspartikeladjuvant
EP1549135A4 (en) VACCINE COMPOSITIONS AND AUXILIARY
IS7831A (is) Bóluefni
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
AU2002307971A1 (en) Vaccine against the nile fever virus
EP1565583A4 (en) HIV VACCINE FORMULATIONS
NO20033829L (no) Virusdrepende preparater
NO20040995L (no) Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
DE60328408D1 (de) Impfstoff
MA26270A1 (fr) Vaccin contre la variole
DK1372712T3 (da) Vaccine mod equint herpesvirus
EP1395262A4 (en) NUCLEOSIDE-VACCINE-ADJUVANTS
EP1539938A4 (en) CHIMERIC GB-VIRUS B (GBV-B)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20